FDA accepts Sucampo’s lubiprostone sNDA for review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA has accepted Sucampo's supplemental NDA for lubiprostone (8 mcg) for the treatment of irritable bowel syndrome with constipation. A standard 10-month review would set the clock for an April 29, 2008, user fee date. The sNDA is supported by two Phase III double-blinded, randomized, placebo-controlled trials involving 1,171 adults, followed by one long-term open-label safety and efficacy extension trial involving 522 adults diagnosed with IBS-C. Marketed by Sucampo and Takeda as Amitiza in a higher dosage form (24 mcg), lubiprostone was approved in January 2006 for the treatment of chronic idiopathic constipation in adults...
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.